The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020

This review fully describes the coronavirus 3CL(pro) peptidomimetic inhibitors and nonpeptidic small molecule inhibitors developed from 2010 to 2020. Specifically, the structural characteristics, binding modes and SARs of these 3CL(pro) inhibitors are expounded in detail by division into two categor...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuzhi, Liang, Chengyuan, Xin, Liang, Ren, Xiaodong, Tian, Lei, Ju, Xingke, Li, Han, Wang, Yongbo, Zhao, Qianqian, Liu, Hong, Cao, Wenqiang, Xie, Xiaolin, Zhang, Dezhu, Wang, Yu, Jian, Yanlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409838/
https://www.ncbi.nlm.nih.gov/pubmed/32810751
http://dx.doi.org/10.1016/j.ejmech.2020.112711
_version_ 1783568134866731008
author Liu, Yuzhi
Liang, Chengyuan
Xin, Liang
Ren, Xiaodong
Tian, Lei
Ju, Xingke
Li, Han
Wang, Yongbo
Zhao, Qianqian
Liu, Hong
Cao, Wenqiang
Xie, Xiaolin
Zhang, Dezhu
Wang, Yu
Jian, Yanlin
author_facet Liu, Yuzhi
Liang, Chengyuan
Xin, Liang
Ren, Xiaodong
Tian, Lei
Ju, Xingke
Li, Han
Wang, Yongbo
Zhao, Qianqian
Liu, Hong
Cao, Wenqiang
Xie, Xiaolin
Zhang, Dezhu
Wang, Yu
Jian, Yanlin
author_sort Liu, Yuzhi
collection PubMed
description This review fully describes the coronavirus 3CL(pro) peptidomimetic inhibitors and nonpeptidic small molecule inhibitors developed from 2010 to 2020. Specifically, the structural characteristics, binding modes and SARs of these 3CL(pro) inhibitors are expounded in detail by division into two categories: peptidomimetic inhibitors mainly utilize electrophilic warhead groups to covalently bind the 3CL(pro) Cys145 residue and thereby achieve irreversible inhibition effects, whereas nonpeptidic small molecule inhibitors mainly interact with residues in the S1’, S1, S2 and S4 pockets via hydrogen bonds, hydrophobic bonds and van der Waals forces. Based on the emerging PROTAC technology and the existing 3CL(pro) inhibitors, 3CL(pro) PROTAC degraders are hypothesised to be next-generation anti-coronavirus drugs.
format Online
Article
Text
id pubmed-7409838
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-74098382020-08-07 The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020 Liu, Yuzhi Liang, Chengyuan Xin, Liang Ren, Xiaodong Tian, Lei Ju, Xingke Li, Han Wang, Yongbo Zhao, Qianqian Liu, Hong Cao, Wenqiang Xie, Xiaolin Zhang, Dezhu Wang, Yu Jian, Yanlin Eur J Med Chem Review Article This review fully describes the coronavirus 3CL(pro) peptidomimetic inhibitors and nonpeptidic small molecule inhibitors developed from 2010 to 2020. Specifically, the structural characteristics, binding modes and SARs of these 3CL(pro) inhibitors are expounded in detail by division into two categories: peptidomimetic inhibitors mainly utilize electrophilic warhead groups to covalently bind the 3CL(pro) Cys145 residue and thereby achieve irreversible inhibition effects, whereas nonpeptidic small molecule inhibitors mainly interact with residues in the S1’, S1, S2 and S4 pockets via hydrogen bonds, hydrophobic bonds and van der Waals forces. Based on the emerging PROTAC technology and the existing 3CL(pro) inhibitors, 3CL(pro) PROTAC degraders are hypothesised to be next-generation anti-coronavirus drugs. Elsevier Masson SAS. 2020-11-15 2020-08-06 /pmc/articles/PMC7409838/ /pubmed/32810751 http://dx.doi.org/10.1016/j.ejmech.2020.112711 Text en © 2020 Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Liu, Yuzhi
Liang, Chengyuan
Xin, Liang
Ren, Xiaodong
Tian, Lei
Ju, Xingke
Li, Han
Wang, Yongbo
Zhao, Qianqian
Liu, Hong
Cao, Wenqiang
Xie, Xiaolin
Zhang, Dezhu
Wang, Yu
Jian, Yanlin
The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020
title The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020
title_full The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020
title_fullStr The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020
title_full_unstemmed The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020
title_short The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020
title_sort development of coronavirus 3c-like protease (3cl(pro)) inhibitors from 2010 to 2020
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409838/
https://www.ncbi.nlm.nih.gov/pubmed/32810751
http://dx.doi.org/10.1016/j.ejmech.2020.112711
work_keys_str_mv AT liuyuzhi thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT liangchengyuan thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT xinliang thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT renxiaodong thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT tianlei thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT juxingke thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT lihan thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT wangyongbo thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT zhaoqianqian thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT liuhong thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT caowenqiang thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT xiexiaolin thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT zhangdezhu thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT wangyu thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT jianyanlin thedevelopmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT liuyuzhi developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT liangchengyuan developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT xinliang developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT renxiaodong developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT tianlei developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT juxingke developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT lihan developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT wangyongbo developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT zhaoqianqian developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT liuhong developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT caowenqiang developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT xiexiaolin developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT zhangdezhu developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT wangyu developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020
AT jianyanlin developmentofcoronavirus3clikeprotease3clproinhibitorsfrom2010to2020

Ejemplares similares